Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Intravascular Lithotripsy: Outcomes and Trends in the Treatment of Calcified Coronary Lesions

Lately, the complexity of percutaneous coronary artery interventions (PCI) has seen an increase, mainly driven by the increasing prevalence of coronary lesion calcification, which represents a significant challenge for interventionists. Untreated calcification might result in insufficient stent expansion, a high risk factor of thrombosis and instent restenosis. 

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Historically, several devices have been used to treat calcification, such as non-compliant high pressure balloons, cutting or scoring balloons and atherectomy. However, these methods can have limitations to effectively modify calcium. Since 2021, intravascular lithotripsy (IVL) has emerged as a promising solution, with safety and efficacy rates higher than 90%.

The aim of this study was to assess the trends and outcomes of IVL, rotational/orbital atherectomy, or both among patients undergoing PCI in Michigan, US. 

Primary end point was adverse cardiovascular events (MACE), defined as the combination of in-hospital mortality, stroke, periprocedural acute MI, coronary perforation or tamponade. Another variable was procedural success. 

Read also: Edge-to-Edge Repair for Right Ventricular Function Deterioration.

The study included 42,440 patients treated with PCI between 2021 and 2022, mean age 72, mainly men. IVL was used in 2.57%, atherectomy in 4.10%, and both in 0.57% of cases. During the study period, IVL use increased from 0.04% in 2021 to 4.28% in 2022, while the use of atherectomy dropped from 4.41% to 3.63%. The anterior descending was the most frequently treated artery both with IVL and atherectomy. 

There were no significant differences in MACE rate (4.3% vs. 5.4%; P = 0.23) or procedural success (89.4% vs. 89.1%; P = 0.88) between patients treated with IVL and those treated with atherectomy. Only 15.6% of patients treated with IVL in the contemporary practice were similar to the population included in the relevant IVL the clinical trials. Among these patients (n = 169), MACE (0.0%) and procedural success rates (94.7%) were comparable to the outcomes reported by the relevant IVL studies. 

Conclusion

Since its approval, the use of IVL has seen a significant increase and is, at present, the go-to technique to modify coronary plaque. Both IVL and atherectomy have been associated to similar rates and have generally few complications, and high procedural success rates. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Contemporary Trends and Outcomes of Intravascular Lithotripsy in Percutaneous Coronary Intervention Insights From BMC2.

Reference: Devraj Sukul, MD, MSC et al J Am Coll Cardiol Intv 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...